Price movement over the last 24 hours
Alcon AG vs Lamb Weston Holdings Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Lamb Weston Holdings Inc trades at $46.21 (market cap $6.42B). The key difference: Alcon AG is far larger — about 5.1× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| ALC | LW | |
|---|---|---|
Market Cap | $32.69B | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $66.57 |
52-Week Low | $62.02 | $38.48 |
Enterprise Value | $36.28B | $10.39B |
Dividend Yield | 0.54% | 3.27% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Lamb Weston (LW) trades at $46.51, up 1.31% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $0.72, exceeding the $0.626 estimate, and maintains a P/E of 21.64 and P/S of 0.99. Recent news highlights its 'Focus to Win' strategy driving North America volume gains and cost savings, while activist investors like Starboard Value push for operational improvements.
The outlook is cautiously optimistic, supported by earnings momentum and strategic initiatives, but risks include a class-action lawsuit, margin pressures, and high debt levels. Analyst consensus is mixed with 35% buy ratings, reflecting balanced sentiment amid turnaround efforts and legal overhangs.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →